We believe Billerud’s announcement to pursue a more cautious investment strategy in the US could reduce its capex needs by cSEK5bn–7bn. Moreover, we believe the risk in our optimistic scenario has diminished, due to market improvements and recent price rises on key products. We reiterate our BUY and have increased our target price to SEK140 (130) also reflecting the balance sheet turning increasingly overcapitalised, which should raise expectations of excess-cash distribution.
A director at Odfjell SE sold 12,300 shares at 186.780NOK and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
A director at Orkla ASA bought 20,000 shares at 82.100NOK and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Coloplast A/S - Invitation to Coloplast's Meet the Management event on 6 June 2024 (gentle reminder) The event will take place on Thursday, 6 June 2024 at Coloplast’s HeadquartersHoltedam 3, 3050 Humlebaek, Denmarkfrom 11.30 - 18.00 CEST (Central European Summer Time) Coloplast invites institutional investors, equity analysts and media to attend our 2024 Meet the Management event.The event will be held in person at our headquarters in Humlebaek, Denmark, with the option to join us virtually for the plenary session.The purpose of the event is to provide participants with the opportuni...
Following a rather mixed Q1 report, our 2024–2026e clean EPS are virtually unchanged. We reiterate our BUY and have raised our target price to DKK440 (400) on a slightly raised SOTP multiple approach. We like the continued earnings quality improvement and further value-creation potential through an exit from Cement.
FLSmidth & Co. Group Interim Report for Q1 2024: Strong gross margin leading to continued improvement in profitability COMPANY ANNOUNCEMENT NO. 8-2024 15 May 2024, Copenhagen, Denmark Highlights in Q1 2024 Mining order intake showed organic growth of 3% reflecting stable Service market and large Products order winsMining revenue declined organically by 11% due to timing of order executionGroup gross margin of 29.2% driven primarily by strong margin execution in MiningAdjusted Mining EBITA margin of 11.5% driven by continued strong execution and realised synergies Good progression...
Coloplast udvider Luja™-portefølje med nyt kateter til kvinder Engangskateteret gør det muligt for kvinder at tømme blæren i et frit flow1, hvilket nedsætter risikoen for urinvejsinfektioner2. Luja-platformen er med sin Micro-hole Zone Technology en ny generation af intermitterende engangskatetre til mennesker med behov for hjælp til at tømme deres blære. Efter en vellykket lancering af Luja til mandlige kateterbrugere lancerer Coloplast nu Luja til kvinder. ”Vi har modtaget rigtig god feedback for Luja til mænd i vores produktevalueringer. Næsten alle sundhedsprofessionelle anbefaler kat...
Coloplast expands its Luja™ portfolio with next generation catheter for women The female intermittent catheter enables complete bladder emptying in one free flow1, aiming to reduce the risk of urinary tract infections2. Following the successful launch of Luja with Micro-hole Zone Technology, a next generation intermittent catheter for men, Coloplast is now launching Luja for women. “So far, we have received great feedback on Luja for men in our product evaluations. Nearly all healthcare professionals would recommend the male catheter to their patients3, and sev...
We have raised our Chemical Tankers rate estimates on the c7% increase QOQ in Q1 and with expectations for further growth in Q2, supported by an outlook for improved chemical production and limited supply ahead. We estimate a double-digit dividend yield through 2026e despite a modest payout ratio, and believe Odfjell screens as an attractive exposure to the tanker segment at an average 2024–2025e EV/EBITDA of 3.7x, versus the broader tanker peer group at 4.5x. We reiterate our BUY, and have rais...
The Q1 results were above our forecasts, but cash flow was weak. We expect the key focus ahead to be the need for a new bank facility, which we are concerned could come at an increased financial cost. We have made minor estimate changes and reiterate our SELL and NOK21 target price.
Elopak reported strong Q1 results, with the EBITDA margin in its European operations beating our and consensus forecast. We see the potential for an increased group EBITDA margin target at the CMD in September. We have raised our 2025–2026e EPS by 7%, and in turn our target price to NOK37 (34). At the same time, we believe margins are at the high end of normalised levels, and struggle to see material upside potential from here. Trading at a 2025e P/E of ~12x, and with limited organic top-line gr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.